The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Abstract The World Health Organization classification and definition of “myeloid sarcoma” is
imprecise and misleading. A more accurate term is “extramedullary acute myeloid leukemia …

Abstract Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented
challenges for hematologists for decades. Despite numerous clinical studies, outcomes are …

Acute myeloid leukaemia (AML) is the commonest indication for allogeneic stem cell
transplantation (allo‐SCT) worldwide. The accumulated experience of allografting in AML …

The azanucleosides azacitidine and decitabine are currently used for the treatment of acute
myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible …

Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous
hematopoietic stem cell disease that may be cured in eligible patients with intensive …

Relapse of the original disease is a major cause of death after allogeneic hematopoietic cell
transplantation for acute leukemias. There is growing evidence that relapses may be …

The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but
have otherwise very heterogeneous biological and genetic characteristics. Clinical features …